News | February 23, 2022
ACUITE upgrades ratings of Bal Pharma
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
Granules India has reported consolidated financial results for the period ended December 31, 2021
Biocon has reported consolidated financial results for the period ended December 31, 2021
Occupancy is expected to be in the range of 60-62% while Average Revenue Per Occupied Bed (ARPOB) is expected to expand by least 6% in FY2022
The stability is led by healthy demand in the domestic and emerging markets
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Ind-Ra continues to expect IPM’s revenue to grow over 12% yoy in FY22
Cipla has reported consolidated financial results for the period ended September 30, 2021
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Subscribe To Our Newsletter & Stay Updated
